Poland · Delayed Price · Currency is PLN Pure Biologics Statistics
Total Valuation
Pure Biologics has a market cap or net worth of PLN 26.69 million. The enterprise value is 42.12 million.
| Market Cap | 26.69M |
| Enterprise Value | 42.12M |
Important Dates
The next confirmed earnings date is Wednesday, September 30, 2026.
| Earnings Date | Sep 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pure Biologics has 12.24 million shares outstanding. The number of shares has increased by 108.92% in one year.
| Current Share Class | 12.24M |
| Shares Outstanding | 12.24M |
| Shares Change (YoY) | +108.92% |
| Shares Change (QoQ) | +64.06% |
| Owned by Insiders (%) | 3.58% |
| Owned by Institutions (%) | 0.50% |
| Float | 11.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -1.63 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.09
| Current Ratio | 0.09 |
| Quick Ratio | 0.08 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.67 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -211.74% |
| Return on Invested Capital (ROIC) | -810.73% |
| Return on Capital Employed (ROCE) | 40.48% |
| Weighted Average Cost of Capital (WACC) | 8.04% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.53M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.20% in the last 52 weeks. The beta is 0.25, so Pure Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | -49.20% |
| 50-Day Moving Average | 2.37 |
| 200-Day Moving Average | 4.20 |
| Relative Strength Index (RSI) | 49.87 |
| Average Volume (20 Days) | 336,284 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -26,000 |
| Operating Income | -6.64M |
| Pretax Income | -9.10M |
| Net Income | -10.73M |
| EBITDA | -6.52M |
| EBIT | -6.64M |
| Earnings Per Share (EPS) | -1.57 |
Balance Sheet
The company has 1.02 million in cash and 16.45 million in debt, with a net cash position of -15.42 million or -1.26 per share.
| Cash & Cash Equivalents | 1.02M |
| Total Debt | 16.45M |
| Net Cash | -15.42M |
| Net Cash Per Share | -1.26 |
| Equity (Book Value) | -16.39M |
| Book Value Per Share | -1.34 |
| Working Capital | -16.39M |
Cash Flow
| Operating Cash Flow | -8.63M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 92,250 |
| Net Borrowing | -32,000 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pure Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -108.92% |
| Shareholder Yield | -108.92% |
| Earnings Yield | -40.18% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |